Int J Gynaecol Obstet. 2010 Oct;111(1):95-100. doi: 10.1016/j.ijgo.2010.07.001.
To review current non-pharmacologic and pharmacologic options for ovulation induction in women with polycystic ovary syndrome (PCOS).
This guideline reviews the evidence for the various options for ovulation induction in PCOS.
Ovulation, pregnancy and live birth rates, risks, and side effects are the outcomes of interest.
Published literature was retrieved through searches of Medline using appropriate controlled vocabulary and key words. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. Grey (unpublished) literature was identified through searching the websites of health technology assessment and of health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.
The evidence gathered was reviewed and evaluated by the Reproductive Endocrinology and Infertility Committee of the Society of Obstetricians and Gynaecologists of Canada. The quality of evidence was quantified using the Canadian Task Force on Preventive Health Care.
BENEFITS, HARMS, AND COSTS: Benefits include weight reduction and improvements in ovulation, pregnancy, and live birth rates. Potential harms include medication side effects and multiple pregnancies.
These guidelines have been reviewed and approved by the Reproductive Endocrinology and Infertility Committee of the SOGC.
综述多囊卵巢综合征（PCOS）患者排卵诱导的非药物和药物治疗选择。
本指南综述了 PCOS 患者排卵诱导各种选择的证据。
感兴趣的结局包括排卵、妊娠和活产率、风险和副作用。
通过使用适当的受控词汇和关键词在 Medline 上检索已发表的文献。结果仅限于系统评价、随机对照试验/对照临床试验和观察性研究。通过搜索卫生技术评估和与卫生技术评估相关的机构、临床实践指南集、临床试验注册处以及国家和国际医学专业协会的网站，确定了灰色（未发表）文献。
加拿大妇产科医生学会生殖内分泌和不孕不育委员会对收集到的证据进行了审查和评估。使用加拿大预防保健工作组对证据质量进行了量化。
获益、危害和成本：获益包括体重减轻和排卵、妊娠和活产率的提高。潜在危害包括药物副作用和多胎妊娠。
这些指南已经过 SOGC 生殖内分泌和不孕不育委员会的审查和批准。
